HIV-1 seronegativity in a child with proved perinatal HIV infection on HAART

Sexually Transmitted Infections

Volumn 81, Issue 5, 2005, Pages 377-379

  Desai, Ninad ^a,b   Mathur, M ^a   Abu Lawi, K ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b KINGS COUNTY HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; VIRUS DNA; ZIDOVUDINE;

ARTICLE; CASE REPORT; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; LABORATORY TEST; MEDICAL RECORD; PERINATAL INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROVIRUS; SERODIAGNOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; VIREMIA; VIRUS LOAD; WESTERN BLOTTING;

ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOTTING, WESTERN; CHILD, PRESCHOOL; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 27144471344     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2004.011973     Document Type: Article

References (10)

1. National Institutes of Health. Guidelines for the use of antiretroviral agents in pediatric HIV infection, 25 June 2003. Available at www.aidsinfo.nih.gov/guidelines/default_db2.asp?id = 51, accessed on 12 February, 2004.
2. Centers for Disease Control (CDC). Interpretive criteria used to report western blot results for HIV-1-antibody testing-United States. Morb Mortal Wkly Rep 1991;40:692-5.
3. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1 infection): control of viral replication and absence of HIV 1 specific immune responses. J Virol 2000;74:6984-91.
4. Ruff C, Ray C, Kwon P, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002;76:9481-92.
5. Resino S, Galan I, Bellon JM, et al. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. J Clin Immunol 2003;23:279-89.
6. Saitoh A, Powell CA, Fenton T et al. Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children. J Infect Dis 2004;189:1216-20.
7. Bryson, Y, Pang S, Wei L, Dickover R, et al. Clearance of HIV infection in a perinatally infected infant. N Engl J Med 1995;332:833-8.
8. De Rossi A, Giaquinto C, Del Mistro, A et al. Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child. AIDS 2000;14:1284-6.
9. Fraaij P; Van Rossum A; Wolthers K et al. Initiation of highly active antiretroviral therapy leads to an HIV-specific immune response in a seronegative infant. AIDS 2003;17:138-140.
10. FDA News, FDA approves new rapid HIV test kit. 7 Nov 2002, 02-49, available at www.fda.gov/bbs/topics/NEWS/2002/NEW00852.html, accessed 12 February, 2004.